EXAI Stock Overview
An artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 1/6 |
Past Performance | 0/6 |
Financial Health | 5/6 |
Dividends | 0/6 |
Exscientia plc Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$5.31 |
52 Week High | US$9.12 |
52 Week Low | US$3.86 |
Beta | 0.86 |
11 Month Change | 12.98% |
3 Month Change | -12.38% |
1 Year Change | -20.51% |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -80.41% |
Recent News & Updates
Exscientia: Too Much Pessimism
Jun 10Exscientia: Drug Discovery Platform Attracting Partners And Cash
May 22Recent updates
Exscientia: Too Much Pessimism
Jun 10Exscientia: Drug Discovery Platform Attracting Partners And Cash
May 22Exscientia: A Strategic Hold In The AI-Driven Drug Discovery Sector (Rating Downgrade)
Feb 26Is Exscientia (NASDAQ:EXAI) In A Good Position To Invest In Growth?
Jan 11Earnings Update: Exscientia plc (NASDAQ:EXAI) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Nov 12New Forecasts: Here's What Analysts Think The Future Holds For Exscientia plc (NASDAQ:EXAI)
Aug 31We're Keeping An Eye On Exscientia's (NASDAQ:EXAI) Cash Burn Rate
Aug 25Broker Revenue Forecasts For Exscientia plc (NASDAQ:EXAI) Are Surging Higher
Jul 21Exscientia (NASDAQ:EXAI) Is In A Good Position To Deliver On Growth Plans
Apr 22We're Not Very Worried About Exscientia's (NASDAQ:EXAI) Cash Burn Rate
Dec 30The Exscientia plc (NASDAQ:EXAI) Analysts Have Been Trimming Their Sales Forecasts
Aug 31Exscientia: Using AI To Power Drug Development
Aug 15Companies Like Exscientia (NASDAQ:EXAI) Can Afford To Invest In Growth
May 29Exscientia: Drug Discovery Using AI For Sanofi And Self-Owned Pipeline
Apr 12Bullish: Analysts Just Made A Sizeable Upgrade To Their Exscientia plc (NASDAQ:EXAI) Forecasts
Jan 09Shareholder Returns
EXAI | US Biotechs | US Market | |
---|---|---|---|
7D | 11.6% | -1.3% | 0.4% |
1Y | -20.5% | 7.7% | 22.9% |
Return vs Industry: EXAI underperformed the US Biotechs industry which returned 6.7% over the past year.
Return vs Market: EXAI underperformed the US Market which returned 23.3% over the past year.
Price Volatility
EXAI volatility | |
---|---|
EXAI Average Weekly Movement | 10.9% |
Biotechs Industry Average Movement | 10.5% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.5% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: EXAI's share price has been volatile over the past 3 months.
Volatility Over Time: EXAI's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 483 | Dave Hallett | www.exscientia.ai |
Exscientia plc, an artificial intelligence (AI) driven Pharma-tech company, engages in design and develop differentiated medicines for diseases with high unmet patient needs. The company’s lead product candidate GTAEXS617, a CDK7 inhibitor, which is currently in a Phase 1/2 trial to manage the potential toxicities associated with CDK7 as well as optimizing pharmacokinetics for maximizing on-target efficacy. It is also involved in the development of EXS4318, a PKC-theta inhibitor, under Phase 1 clinical trial for inflammation and immunology indications; EXS74539, a LSD1 inhibitor, under preclinical studies for SCLC, AML, and potential additional indications; EXS73565, a MALT1 inhibitor, under preclinical studies for multiple hematology indications; and DSP-0038, currently in Phase 1 studies.
Exscientia plc Fundamentals Summary
EXAI fundamental statistics | |
---|---|
Market cap | US$652.09m |
Earnings (TTM) | -US$163.77m |
Revenue (TTM) | US$24.83m |
27.0x
P/S Ratio-4.1x
P/E RatioIs EXAI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
EXAI income statement (TTM) | |
---|---|
Revenue | UK£19.61m |
Cost of Revenue | UK£26.35m |
Gross Profit | -UK£6.75m |
Other Expenses | UK£122.58m |
Earnings | -UK£129.33m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.02 |
Gross Margin | -34.40% |
Net Profit Margin | -659.56% |
Debt/Equity Ratio | 0.09% |
How did EXAI perform over the long term?
See historical performance and comparison